Liège-based Convert Pharmaceuticals SA has been granted a total of €13.6m in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive support by the Walloon region and funds from the European Eurostars programme.
AstraZeneca (AZ) and Bavarian Nordic (BN) combine BNs cancer vaccine CV301 and AZs PD-L1 checkpoint blocker durvalumab in an investigator-sponsored trail to check synergistic effects in patients with colorectal and pancreatic cancer overexpressing CEA and MUC-1.
The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended three medicines, two thereof orphan drugs, at its February 2018 meeting.
Everybody wants green production. Bioeconomy progress, however, must become more visible to consumers and let the civil society get involved to ensure socially robust innovation and perception, according to the BioBioSTEP project.
A new method that determines the mode of action underlying antimicrobial compounds could help overcome a major stumbling block in the ongoing effort to discover new antibiotics. Using it, reseachers from ETH Zurich zeroed in on compounds directed against tuberculosis.
Virtual oncology company Cullinan Oncology, LLC has selecteed monoclonal antibody provider MAB Discovery GmbH (Neuried) to develop the first candidate of a target portfolio of 8-10 novel antibody therapeutics.
UK researchers headed by Michael Blackman have found out that a proteolytic cascade regulates release of merozoites of the human malaria parasite Plasmodium falciparum from host red blood cells. Inhibitition paves the way to block the parasites egress.
Spanish specialist for sea-derived synthetic oncology drugs, PharmaMar SA, has inked a licence agreement with US antibody drug conjugate (ADC) company Seattle Genetics Inc. PharmaMar will provide fully-synthetic toxic payloads.
In a strategic acquisition, Roche has completed its capabilities to use Big data to build new business cases in digital diagnostics solutions and personalised healthcare. The pharma major agreed to pay US$1.9bn to take over the US specialist for digital electronic medical records, Flatiron Health Inc.